Citius Pharmaceuticals, Inc. (CTXR) - 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2026 Annual Meeting of Stockholders held on April 6, 2026. The Company is incorporated in Nevada and its common stock trades on The Nasdaq Capital Market under the symbol CTXR.
Key Financial Metrics
This filing is a current report regarding corporate governance events and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity is not provided in this document.
Material Changes and Voting Results
The primary material event reported is the election of the Board of Directors and the ratification of the independent auditor.
- Board of Directors Election: Stockholders elected seven directors for a one-year term expiring in 2027. All nominees received a majority of votes cast.
- Auditor Ratification: Stockholders ratified the selection of Wolf & Company, P.C. as the independent registered public accounting firm for the fiscal year ending September 30, 2026.
| Nominee | For | Withheld | Broker Non-Votes |
|---|---|---|---|
| Leonard Mazur | 2,391,069 | 1,071,618 | 6,660,992 |
| Myron Holubiak | 2,390,702 | 1,071,985 | 6,660,992 |
| Suren Dutia | 2,311,462 | 1,151,225 | 6,660,992 |
| Dr. Eugene Holuka | 2,391,419 | 1,071,268 | 6,660,992 |
| Dennis M. McGrath | 2,449,029 | 1,013,658 | 6,660,992 |
| Robert Smith | 2,485,904 | 976,783 | 6,660,992 |
| Carol Webb | 2,422,082 | 1,040,605 | 6,660,992 |
Auditor Vote Breakdown: 8,593,946 For; 855,866 Against; 673,867 Abstaining; 0 Broker Non-Votes.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is strictly a disclosure of voting results.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to contextualize the "Broker Non-Votes" (6,660,992), which represent a significant portion of the voting power not cast on director elections.
- Confirm the tenure of the newly elected directors, which is one year expiring at the 2027 annual meeting.
- Review the Company's most recent 10-K or 10-Q for financial performance data, as this 8-K does not include financial metrics.